You are here

Sundt Constructon receives CEO Cancer Gold Standard™ Accreditation

June 10, 2011
Cary, NC

Sundt Construction, Inc. has received CEO Cancer Gold Standard™ accreditation, recognizing the company’s commitment to reducing cancer risk by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring access to quality treatment for their own employees and their covered family members.   Sundt is the first construction company in the United States to achieve Gold Standard accreditation.  The 121-year-old firm is the 54th largest general contractor in the United States and owned entirely by its 1,500 employees.

Christopher A. Viehbacher, chief executive officer of Sanofi, chairs the CEO Roundtable on Cancer, a nonprofit organization of cancer-fighting CEOs who created the CEO Cancer Gold Standard™, in collaboration with the National Cancer Institute, many of its designated cancer centers, and leading health non-profit organizations and professionals. Today, more than two million employees and family members are benefiting from the vision and leadership of employers like Sundt who have chosen to become Gold Standard accredited.

“This Gold Standard accreditation is an acknowledgement of the leadership of J. Doug Pruitt, Chairman & CEO of Sundt, and his work on behalf of the health of employees and their families,” said Christopher A. Viehbacher, CEO of Sanofi. “I hope Sundt’s efforts will encourage other employers, large and small, to become Gold Standard accredited.”

The CEO Cancer Gold Standard™ calls for companies to evaluate their health benefits and corporate culture and take extensive, concrete actions in five key areas of health and wellness to fight cancer in the workplace. To earn Gold Standard accreditation, a company must establish programs to reduce cancer risk by discouraging tobacco use; encouraging physical activity; promoting healthy diet and nutrition; detecting cancer at its earliest stages; and providing access to quality care, including participation in clinical trials.